首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi

市場調查報告書

商品編碼

1577049

DNA合成市場、機會、成長動力、產業趨勢分析與預測，2024-2032

DNA Synthesis Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月07日 | 出版商:

Global Market Insights Inc. | 英文 237 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球DNA 合成市場在2023 年將達到40 億美元，預計2024 年至2032 年複合年成長率為18.9%。日益採用所推動的。對合成生物學研究的關注得到了大量研發投資和對 DNA 研究的日益重視的支持。此類資金支持技術進步並放大合成生物學在基因組領域的潛力，推動市場成長。

DNA 合成涉及透過在實驗室中化學合成核苷酸序列來人工創建 DNA 分子。這些序列用於基因工程、研究和生物技術。

市場依服務分為寡核苷酸合成和基因合成。 2023 年，寡核苷酸合成在分子診斷、基因測試、合成生物學和基因編輯中的作用推動下，以 58% 的佔有率引領市場。自動合成器和高通量平台等技術進步提高了寡核苷酸合成的可擴展性和效率，進一步推動了市場的發展。

市場也依方法分為基於晶片的合成、基於PCR的酶合成和固相合成。固相合成在2023 年佔據了重要的市場佔有率，預計到2032 年將達到90 億美元。。此方法的可擴展性和成本效益使其適用於研究和工業應用。

按應用分類，DNA 合成市場包括研發、診斷和治療。研發領域將在 2023 年引領市場，預計在分析期間複合年成長率為 19.3%。該細分市場的重要市場佔有率歸因於其在推進生物技術和藥物研究方面的作用。藥物發現、實驗研究和基因工程中對客製化 DNA 序列的需求不斷成長，推動了 DNA 合成的成長。

該市場按最終用途分為生物製藥公司、學術和研究機構以及合約研究組織。生物製藥公司領域預計從2024 年到2032 年將以18.4% 的複合年成長率成長。。生物製藥公司正在投資 DNA 合成技術，以加快藥物發現和開發，從而開發新療法。

2023年，北美以36.5%的佔有率引領全球DNA合成市場，預計在分析期間複合年成長率為18.4%。該地區的主導地位得益於強大的研發基礎設施以及專注於合成生物學和基因編輯的關鍵參與者和領先研究機構的集中。這些合作凸顯了該地區在推動關鍵醫療保健解決方案 DNA 合成技術方面的領導地位。

產業生態系統分析
產業影響力
- 成長動力
  - 全球疾病盛行率不斷上升
  - 合成生物學領域技術的快速進步
  - 研究與開發（R and D）活動投資不斷增加
- 產業陷阱與挑戰
  - 嚴格的政府法規和指導方針
  - 成本高、潛在的生物安全、生物安保和倫理問題
成長潛力分析
監管環境
- 美國
- 歐洲
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
- Thermo fisher scientific Inc.
- Eurofins scientific
- GenScript biotech corporation
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按服務分類，2018 年 - 2032 年

主要趨勢
寡核苷酸合成
- 標準寡核苷酸合成
- 客製化寡核苷酸合成
基因合成
- 客製化基因合成
- 基因庫合成

第 6 章：市場估計與預測：依方法，2018 - 2032

主要趨勢
固相合成
基於PCR的酶合成
基於晶片的合成

第 7 章：市場估計與預測：按應用分類，2018 年 - 2032 年

主要趨勢
研究與開發
診斷
療法

第 8 章：市場估計與預測：依最終用途，2018 年 - 2032 年

主要趨勢
生物製藥公司
學術及研究機構
合約研究組織

第 9 章：市場估計與預測：按地區分類，2018 年 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 中東和非洲其他地區

第 10 章：公司簡介

BIOMATIK
Bioneer Corporation
Eton Bioscience, Inc.
Eurofins Scientific
GenScript Biotech Corporation
IBA Lifesciences GmbH
Integrated DNA Technologies, Inc.
Kaneka Eurogentec SA
LGC Biosearch Technologies
OriGene Technologies, Inc.
ProMab Biotechnologies, Inc.
ProteoGenix
Quintara Biosciences
Synbio Technologies
Thermo Fisher Scientific Inc.
Twist Bioscience Corporation

簡介目錄

Product Code: 6000

The Global DNA Synthesis Market garnered USD 4 billion in 2023 and is projected to grow at a CAGR of 18.9% from 2024 to 2032. This growth is driven by advancements in synthetic biology and gene editing technologies, such as CRISPR, and the increasing adoption of precision medicine. The focus on synthetic biology research is supported by substantial R&D investments and an expanding emphasis on DNA studies. Such funding supports technological advancements and amplifies synthetic biology's potential in the genome sector, driving market growth.

DNA synthesis involves the artificial creation of DNA molecules by chemically synthesizing nucleotide sequences in a lab. These sequences are used in genetic engineering, research, and biotechnology.

The market is segmented by service into oligonucleotide synthesis and gene synthesis. In 2023, oligonucleotide synthesis led the market with a 58% share, driven by its role in molecular diagnostics, genetic testing, synthetic biology, and gene editing. Technological advancements, such as automated synthesizers and high-throughput platforms, further boost the market by enhancing the scalability and efficiency of oligonucleotide synthesis.

The market is also segmented by method into chip-based synthesis, PCR-based enzyme synthesis, and solid-phase synthesis. Solid-phase synthesis held a significant market share in 2023 and is projected to reach USD 9 billion by 2032. Its dominance is due to its efficiency and adaptability in constructing DNA sequences on solid supports, allowing for step-by-step nucleotide addition. The method's scalability and cost-effectiveness make it suitable for both research and industrial applications.

By application, the DNA synthesis market includes research and development, diagnostics, and therapeutics. The research and development segment led the market in 2023 and is projected to grow at a CAGR of 19.3% during the analysis period. This segment's significant market share is due to its role in advancing biotechnology and pharmaceutical research. The rising demand for custom DNA sequences in drug discovery, experimental studies, and genetic engineering propels DNA synthesis growth.

The market is segmented by end use into biopharmaceutical companies, academic & research institutes, and contract research organizations. The biopharmaceutical companies segment is projected to grow at a CAGR of 18.4% from 2024 to 2032. This growth is driven by the demand for personalized medicine, where DNA synthesis is crucial in creating treatments tailored to individual genetic profiles. Biopharmaceutical firms are investing in DNA synthesis technologies to expedite drug discovery and development, leading to novel therapies.

In 2023, North America led the global DNA synthesis market with a 36.5% share and is projected to grow at a CAGR of 18.4% during the analysis period. The region's dominance is supported by a strong R&D infrastructure and a concentration of key players and leading research institutions focused on synthetic biology and gene editing. Collaborations highlight the region's leadership in advancing DNA synthesis technologies for critical healthcare solutions.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing prevalence of diseases globally
  - 3.2.1.2 Rapid technology advancements in the field of synthetic biology
  - 3.2.1.3 Rising investments towards research and development (R and D) activities
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Stringent government regulations and guidelines
  - 3.2.2.2 High cost, potential biosafety, biosecurity and ethical issues
3.3 Growth potential analysis
3.4 Regulatory landscape
- 3.4.1 U.S.
- 3.4.2 Europe
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
- 4.1.1 Thermo fisher scientific Inc.
- 4.1.2 Eurofins scientific
- 4.1.3 GenScript biotech corporation
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Service, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Oligonucleotide synthesis
- 5.2.1 Standard oligonucleotide synthesis
- 5.2.2 Custom oligonucleotide synthesis
5.3 Gene synthesis
- 5.3.1 Custom gene synthesis
- 5.3.2 Gene library synthesis

Chapter 6 Market Estimates and Forecast, By Method, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Solid-phase synthesis
6.3 PCR-based enzyme synthesis
6.4 Chip-based synthesis

Chapter 7 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Research and development
7.3 Diagnostics
7.4 Therapeutics

Chapter 8 Market Estimates and Forecast, By End use, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 Biopharmaceutical companies
8.3 Academic and research institutes
8.4 Contract research organizations

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 Rest of Middle East and Africa